Targeted Precision: Antibody-Drug Conjugates Revolutionize Urothelial Carcinoma Therapy

Despite advancements with immune checkpoint inhibitors, Urothelial carcinoma remains a formidable challenge due to aggressive progression and limited treatment options. However, recent advancements in targeted therapy have provided promising avenues for improved outcomes. Antibody-Drug Conjugates (ADCs) represent a novel approach that combines the specificity of monoclonal antibodies with the cytotoxicity of chemotherapeutic agents, thereby enhancing efficacy while minimizing systemic toxicity. This review explores the role of ADCs in the management of urothelial carcinoma, elucidating their mechanisms of action, clinical efficacy, and future directions in precision oncology.